Biophytis, a Romainville (Seine-Saint-Denis), near Paris-based research company in health and nutrition focusing on metabolic disorders and age-related diseases, has raised €2m (approximately $2.6m) in Series B funding round.
The company intends to use the funding to continue development of its nutraceuticals pipeline and to develop drug candidates derived from nutraceutical active substances for the treatment of metabolic and age-related diseases.
Created in 2006 by CEO Stanislas Veillet and Rene Lafont, professor at Universite Pierre et Marie Curie, Biophytis has two clinically tested proprietary actives in its portfolio.
These are Quinolia(R) for obesity treatment and Bixilia(R) for skin protection against UV radiation. It also includes two drug candidates at the pre-clinical stage in the fields of sarcopenic obesity and age-related macular degeneration.